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Optimizing the management 
of advanced non-small-cell 
lung cancer: a personal view
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The present article is my personal view of how 
to navigate these waters, and although it is written 
especially for patients who like to be the captain of 
their own ship, there is good reason to believe that 
all patients will eventually be managed by similar, if 
not identical, means. Nonetheless, the recommenda-
tions herein should not be construed as appropriately 
reviewed provincial or national guidelines. Finally, if 
appropriate, a clinical trial should always be offered.
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1.  INTRODUCTION
Non-small-cell lung cancer (n s c l c) is a heterogeneous 
collection of entities sharing only three properties: 
they arise in the post-tracheal respiratory tree, they 
are carcinomas, and they are not, morphologically, 
small-cell. This low barrier to entry is reflected in 
the World Health Organization 2004 classification 1, 
which lists 44 subtypes. At least some of these histo-
types are surrogates for a suite of molecular charac-
teristics that both constrain and enable the activities 
of various drugs, classical and new alike 2–8. These 
new discoveries regarding targets and targeted agents 
can now be combined with traditional parameters—
for example, histology and smoking status—and with 
the older drugs into a kind of “modern synthesis,” 
which will allow for a welcome and overdue level of 
sophistication in management.
Nonetheless, there is also a danger of multiplying 
complexity beyond what is necessary: “that which 
can be explained with less is explained in vain with 
more.” Unfortunately, novel biomarker distribution 
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rare paradigm shifts. Just as the nihilism of the 1970s 
gave way to the empiricism of the 1980s and 1990s, 
so the current decade has seen the first truly rational 
therapies based on informed design. In addition, mo-
lecular markers and traditional parameters can now 
be combined to provide a framework of knowledge 
that will guide the application of not just the new 
therapies, but also the older ones that remain effec-
tive. This framework—as important a component of 
the rational paradigm as the new drugs themselves 
are—is necessary to decide who should and, crucial-
ly, who should not receive the various components of 
this rapidly expanding armamentarium. Here, I have 
provided a historical overview of the drug treatment 
of  a-n s c l c , a mini-review of important new data, 
and an integrative approach that tries to ensure that 
patients receive the optimal treatment choice at the 
appropriate time.
The speed at which new knowledge now arrives, 
coupled with the persistent high level of unmet medical 
need, suggests that the traditional pace of evidence-
based review needs to be accelerated. Indeed, the 
increased scope for personalized management consti-
tutes something of a challenge to “business as usual” 
evidence-based medicine. As a result, substantial 
investment on the part of payers, which may or may 
not be possible, will be required. In the meantime, 
some patients may wish and may be financially able 
to take advantage of modern developments before they 
have been fully digested by the public-payer system. 
Responsive clinicians face difficult tradeoffs as they 
try to balance the pros and cons of early adoption 
versus excessive conservatism.
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does not always fall neatly within classical histologic 
subtypes, and practitioners should be prepared for 
subgroups to merge and to fragment in novel ways. 
This novelty will be reflected in the algorithm pre-
sented later, particularly for adenocarcinoma. Note 
that the management of elderly or unfit patients is not 
covered. It must be emphasized that considerable 
uncertainty remains in some of the recommendations.
2.  SOURCES OF HETEROGENEITY
2.1  Goals of Management
In advanced n s c l c  ( a-n s c l c), the most important 
goals are to prolong survival and to relieve or prevent 
symptoms. Efforts to minimize toxicity are also criti-
cal and should focus on avoidance of unnecessary 
toxicity and especially of intolerable toxicity. Some 
novel treatments are considerably less toxic than 
are older drugs; others are at least as problematic, 
although in new and challenging ways.
2.2  Principles of Management: What Has Changed?
The traditional priorities—to provide appropriate 
and realistic information, and to seek and satisfy the 
patient’s wishes—are unchanged. The next task is to 
obtain rapid control of aggressive, symptomatic dis-
ease; to select the correct modality (including radia-
tion, if appropriate) and regimen; and to administer 
treatment sooner rather than later. The potential for 
harm, and strategies for avoidance, should be con-
sidered. What is new is the need to appreciate that 
most patients will receive serial treatments, each 
potentially constraining the choice of what follows. 
The entire course therefore needs to be mapped out, 
at least in a flexible way, at the beginning. An attempt 
should be made to stay within a standard-of-care 
framework. If emerging data make this attempt dif-
ficult, new options should be debated with the patient 
and with colleagues, guided by the patient’s ability 
to access the drug or drugs.
2.3  Sources of Uncertainty
In the absence of adequate biopsy tissue, making 
rational decisions becomes increasingly difficult. 
Unlike many other cancers, n s c l c  often presents in 
an advanced form that is difficult to biopsy properly 
or that results in a biopsy reflective of a diagnostic 
culture of minimalism. Serum studies of tumour-
derived markers may be a way forward, but experi-
ence to date is not encouraging 9.
Lack of adequate tissue apart, the full implica-
tions of many parameters have yet to emerge—for 
example, KRAS mutation status. A transitional phase 
in which decisions will frequently have to be made 
under uncertainty is inevitable. Guidelines, while 
important, cannot resolve all dilemmas. Likewise, 
new knowledge can both raise and lower the level of 
uncertainty. How to cope is the hallmark of the so-
phisticated clinician. Rigid and simplistic guidelines, 
a requirement for absolute proof, and a dogmatic 
adherence to old data are how not to proceed, but 
unnecessary gambling is a similarly poor choice.
2.4  Primum Non Nocere
The ancient precept primum non nocere has always 
posed a challenge for medical oncologists. It is par-
ticularly important to appreciate that there is a tax-
onomy of harm, because subtle forms of harm exist 
and can, with skill, be avoided.
Harm can be active or passive. Passive harm 
arises when, for example, a decision is made to avoid 
treatment and just to observe the patient when active 
intervention is more appropriate. One instance might 
be a decision to forgo maintenance treatment, which 
has now been shown to improve progression-free 
survival (p f s) and the disease control rate, and even 
to prolong survival, as discussed later in this article. 
Another instance of passive harm would be selection 
of an inferior regimen when a superior regimen is 
available—for example, the continued use of doc-
etaxel in patients with non-squamous histology in the 
second line, when a better and less toxic alternative, 
pemetrexed, is available.
Active harm is usually understood to be the cre-
ation of toxicity, although this conception may be too 
limited. Concerning toxicity, however, it is useful to 
consider what the patient wishes to avoid, to what 
the patient is vulnerable, and the consequences that 
would ensue should the worst actually happen. The 
classical and novel regimens all have well-described 
and somewhat variable propensities to cause a range 
of toxicities, a situation that allows for considerable 
personalization of treatment (Table i). A free-access 
Web site (www.predictpatientevents.com) that indi-
vidualizes quantitative risk determination for several 
toxicities has been developed, with more risk models 
in preparation.
Yet recent evidence indicates that another form 
of active harm might be possible: that of direct or 
indirect tumour acceleration. Small-molecule epi-
dermal growth factor receptor (e g f r ) tyrosine kinase 
inhibitors (t k i s) have, in at least three trials, clearly 
or probably exhibited this effect. In t r i b u t e (Tarceva 
Responses in conjunction with Paclitaxel and Car-
boplatin), a failed study of chemotherapy with and 
without erlotinib, patients were analyzed by KRAS 
status; KRAS-mutant patients on chemotherapy with 
erlotinib had a statistically worse survival than did 
KRAS-mutant patients on chemotherapy with place-
bo 16. In b r .21, which tested erlotinib against placebo 
in the second and third lines, KRAS-mutant patients 
also had worse survival [hazard ratio (h r ): 1.67], but 
given the small numbers analyzed, the p value was not 
significant 4. Finally, the Southwest Oncology Group A-NSCLC: A PERSONAL VIEW
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t a b l e  i   Summary of grades 3 and 4 chemotherapy toxicity from selected large trials
Reference Regimen Dose Schedule Grade 3/4 toxicities (% of patients)
(mg/m2) Febrile Anemia Nausea/ Peripheral Platelets Renal
neutropenia vomiting neuropathy
Kosmidis et al., 2002 10 Carboplatin, a u c  6 Day 1, 1 5 4 8 2 0
paclitaxel 200 day 1,
(over 
3 hours)
every 3 weeks
Gemcitabine, 1000 Days 1, 8; 2 2 7 6 1 <1
paclitaxel 200 day 1;
(over 
3 hours)
every 3 weeks
Carboplatin, 5.2 0 n r n r 1.6 n r
paclitaxel,
bevacizumab
Schiller et al., 2002 11 Cisplatin, 75 Day 2, 16 13 25/24 5 6 3a
paclitaxel 135 day 1,
(over 
24 hours)
every 3 weeks
Cisplatin, 75 Day 1, 11 15 14/21 5 3 3a
docetaxel 75 day 1,
every 3 weeks
Cisplatin, 100 Day 1; 4b 28b 37/35 9 50b 9a,b
gemcitabine 100 days 1, 8, 15;
every 4 weeks
Carboplatin, a u c  6 Day 1, 4b 10 9b/8b 10 10 1a
paclitaxel 225 day 1
(over 
3 hours)
Fossella et al., 2003 12 Cisplatin, 100 Day 1; 5 24 16/16 4 4 n r
vinorelbine 25 days 1, 8, 15, 22; (sensory)
every 4 weeks
Cisplatin, 75 Day 1, 5 7c 10/8c 4 3 n r
docetaxel 75 day 1, (sensory)
every 3 weeks
Carboplatin, a u c  6 Days 1, 8; 4 10c 6/4c 1 7 n r
docetaxel 100  day 8 (sensory)
Georgoulias et al., 2005 13 Cisplatin, 80 Day 8; n r 6 15d n r 6 3
vinorelbine 30 days 1, 8
Gemcitabine, 1000 Days 1, 8; n r 2 2d n r 4 0
docetaxel 100 day 8
Grønberg et al., 2007 14 Carboplatin, a u c  5 Day 1, n r 12 n r n r 24 n r
pemetrexed 500 day 1
Carboplatin, a u c  5 Day 1; n r 13 n r n r 54 n r
gemcitabine 1000 days 1, 8;
every 21 days
Scagliotti et al., 2008 15 Cisplatin, 75 Day 1, 1.3 5.6 7.2/6.1 n r 4.1 n r
pemetrexed 500 day 1
a   Grades 3, 4, and 5 renal toxicity.
b   Toxicity was significantly different from that for cisplatin–paclitaxel (p < 0.05).
c   Toxicity was significantly different from that for cisplatin–vincristine (p < 0.01).
d   Toxicity was significantly different between gemcitabine–docetaxel and cisplatin–vincristine (p < 0.001).
n r  = not reported; a u c  = area under the curve.VINCENT
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study 0023, which tested the addition of gefitinib 
(against placebo) in stage iii patients as maintenance 
post chemoradiation, had to be prematurely stopped 
because the gefitinib arm experienced a marked and 
statistically worse survival 17, with the excess deaths 
being attributable to cancer.
The foregoing findings remain unexplained, but 
they cannot easily be dismissed. KRAS mutations are 
definitely, or probably, involved 18. Caution should 
be exercised if these drugs are being considered in 
ex- or current smokers with adenocarcinoma, about 
40% of whom harbour ras-mutated tumours 19. If a 
ras mutation is known to be present, e g f r -t k i s should 
be avoided or used as a last resort.
2.5  The Status Quo Ante
In 1995, a meta-analysis was published establishing 
the benefit of cisplatin-based “second-generation” 
regimens over best supportive care 20. A variety of 
such regimens—for example, cisplatin–etoposide, 
mitomycin–vinblastine–cisplatin—was actively ex-
plored by the Eastern Cooperative Oncology group 
(e c o g) 21, with cisplatin–etoposide exhibiting the 
highest proportion of 1-year survivors (25%). When 
tested later against cisplatin–paclitaxel, cisplatin–
etoposide was only marginally inferior, and then 
only because of the inclusion of stage iiib patients 22. 
In another study, carboplatin–paclitaxel was slightly 
inferior to cisplatin–etoposide in respect of survival, 
but was felt to result in superior quality of life 23. 
These borderline results nonetheless ushered in the 
era of the third-generation platinum doublets, com-
bining either cisplatin or carboplatin with one of 
gemcitabine, vinorelbine, paclitaxel, or docetaxel.
These third-generation regimens, which until 
very recently were the standard of care in the first 
line, exhibit only modest efficacy differences 11,24,25. 
Meta-analyses have shown that chemotherapy is 
better if platinum-based 26; that either gemcitabine-
containing 27 or docetaxel-containing 28 doublets are 
superior; that doublets are better than a single agent, 
but that triplet cytotoxic regimens are not superior 
to a platinum doublet 29; and that cisplatin-based 
doublets are superior to carboplatin-based dou-
blets 30. Furthermore, prolonging treatment beyond 
4–6 cycles, whether with the same or different drugs, 
appears not to prolong survival 31 despite hints that 
p f s or symptom control might be improved 32,33.
The value of second-line chemotherapy was 
demonstrated when docetaxel proved superior to 
placebo in respect of survival and symptom con-
trol 34. Pemetrexed was then compared with docetaxel 
in that setting, with virtually identical objective re-
sponse and survival. Pemetrexed, however, was 
considerably less toxic than docetaxel, and was 
therefore widely approved for that indication 35. A 
subsequent, post-hoc analysis 36 showed that peme-
trexed was superior in p f s (h r: 0.82; p = 0.076) and 
overall survival [o s  (h r: 0.78; p = 0.047)] to docetaxel 
in patients with adenocarcinoma or large-cell (“non-
squamous”) disease, whereas the reverse was true in 
the squamous carcinoma subgroup (p f s h r: 1.40; 
p = 0.046; o s  h r: 0.78; p = 0.047). This unexpected 
finding led to a more restricted approval for peme-
trexed in the second line in some jurisdictions.
It should be noted that the survival h r advantage 
for large-cell disease (0.27) was more impressive than 
that for adenocarcinoma (0.92) 37. Nonetheless, the re-
sponse rate and p f s were both in favour of pemetrexed 
in adenocarcinoma, and these results, together with 
lower toxicity and a shorter infusion time, drove the 
replacement of docetaxel by pemetrexed in all non-
squamous second-line patients. Pemetrexed seems to 
be unusual in this selectivity by histology, and in this 
respect, it might be considered a “fourth-generation” 
type of cytotoxic, in that it is targeted in a manner that 
is clinically exploitable: that is, targeted clinically in 
addition to having a known molecular target. Other 
cytotoxics (first-, second-, and third-generation) are 
not known to be histologically targeted except in the 
sense that they are usually more active in small-cell 
lung cancer than in n s c l c .
A further publication on the pemetrexed work 38 
showed that the drug’s superior tolerability profile 
was particularly important in elderly patients re-
gardless of histology, although younger patients also 
enjoyed considerably less toxicity on pemetrexed. Yet 
another publication from the same study indicated 
that, in the whole patient population, symptom relief 
was correlated with objective response status and 
p f s  39. That analysis implies an importance for treat-
ing symptomatic patients with drugs to which they 
are most likely to respond.
Other studies have examined the role of the 
e g f r-t k is in the second (or third) line. The b r .21 40 
study compared erlotinib with placebo in this set-
ting and showed a significant benefit in survival and 
symptom control for erlotinib, at the cost of skin rash 
and some diarrhea. This result led to the approval of 
erlotinib. It has been claimed that erlotinib benefited 
all subgroups of patients, although certain molecular 
parameters and clinical features seemed to indicate 
considerable selectivity 4,41. Erlotinib is well rec-
ognized as a targeted type of therapy (in the sense 
of having a known molecular target, a driver of the 
malignant phenotype); however, whether erlotinib 
targeted particular subgroups of patients—and if so, 
to what extent—was unclear. In particular, it was not 
clear whether the types of patients who would not 
benefit, and who therefore should not in future be 
offered erlotinib, were identifiable.
Careful scrutiny of the b r .21 subgroup data as 
published reveals that non-smokers exhibited better 
survival improvement than did smokers (h r: 0.42, 
p < 0.001 compared with h r: 0.86, p = 0.141; interaction 
p = 0.0109). Among the smokers, however, the squamous 
patients enjoyed an excellent benefit (h r: 0.66; p = 0.009). A-NSCLC: A PERSONAL VIEW
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This finding raised the question of how well the re-
sidual smokers could have done once the squamous 
patients had been extracted. A subsequent publica-
tion 42 revealed that the h r for ex- or current smokers 
with adenocarcinoma was 0.94 (p = 0.686) and 
that median survival actually favoured placebo 
(5.22 months vs. 4.83 months).
Note, then, the heterogeneity, especially within 
adenocarcinoma: the never-smokers who do well on 
e g f r -t k i s, and the ex- or current smokers who, overall, 
do not do so well. This observation raises the question 
of whether it is useful to consider adenocarcinoma a 
single category. Clearly, from the viewpoints of causa-
tion, prognosis, and e g f r -t k i  therapy, it is not; but the 
present article later shows that, from the viewpoint 
of relative benefit on pemetrexed, it is.
Gefitinib, also an e g f r -t k i , was approved in 
Canada for use after chemotherapy failure, but it was 
withdrawn when the large i s e l (Iressa Survival Evalu-
ation in Lung Cancer) trial (placebo comparison) did 
not show benefit outside of Asia 43. The study patients 
were all strictly chemotherapy-refractory, a situa-
tion different from that in b r .21, in which only 28% 
of patients were refractory. Subsequently, gefitinib 
showed non-inferiority to docetaxel in i n t e r e s t (Iressa 
Non-small Cell Lung Cancer Trial Evaluating Response and 
Survival Against Taxotere) 44 in the second line, and su-
periority in p f s or objective response rate (o r r ) over 
carboplatin–paclitaxel in Asian patients in the first line 
(providing that EGFR is mutated) in i p a s s  (Iressa Pan 
Asia Study) 45. However, in wild-type EGFR patients, 
gefitinib was markedly inferior to chemotherapy in 
respect of o r r  and p f s, and possibly in respect of sur-
vival. The strong indication was that gefitinib should 
not be given to wild-type EGFR never-smokers, and 
that if a patient’s EGFR status is unknown, induction 
chemotherapy (followed by maintenance gefitinib) 
is preferable to a “gamble” with gefitinib induction. 
Gefitinib may be reapproved in Canada, possibly in 
the restricted context of EGFR-mutated cancers.
3.  NEW DEVELOPMENTS IN THE FIRST-LINE 
SYSTEMIC TREATMENT OF A-NSCLC
Several recent, well-conducted randomized trials 
involving pemetrexed, bevacizumab, cetuximab, 
erlotinib, and gefitinib indicate that previous manage-
ment must be reconsidered.
3.1  Pemetrexed
Pemetrexed–cisplatin was tested against gemcitabi-
ne–cisplatin in first-line a-n s c l c  15. This trial (j m d b), 
at 1725 accrued patients, is the largest randomized 
controlled trial ever conducted in this disease. The 
primary goal was non-inferiority in o s , which was 
achieved (h r: 0.94; 95% confidence interval: 0.84 
to 1.05 in favour of pemetrexed–cisplatin). Because 
of the unusual targeted nature of pemetrexed, an 
analysis by histology was pre-specified. As in the 
preceding second-line trial (j m e i), a pronounced dif-
ference by histotype was evident for the pemetrexed 
arm (interaction p = 0.0011): the adenocarcinoma 
(h r: 0.84; p = 0.03) and large-cell patients (h r: 0.67; 
p = 0.03) did better on cisplatin–pemetrexed than 
on cisplatin–gemcitabine, both separately and when 
grouped together as “non-squamous” (h r: 0.81; 
p = 0.005). The opposite was true for the squamous 
patients, who benefited more on gemcitabine–
cisplatin than on pemetrexed–cisplatin (h r: 1.23; 
p = 0.05). Furthermore, objective response rates and 
p f s results either were all significantly different or 
trended in the same direction. One other notewor-
thy finding was that, on pemetrexed–cisplatin, the 
non-squamous patients did better than the squamous 
patients did [median survival time (m s t ): 11.8 months 
vs. 9.4 months], but on gemcitabine–cisplatin, the 
two histologic categories experienced very similar 
survival (m s t : 10.4 months vs. 10.8 months).
Moreover, in ex-smoking, current-smoking, 
and never-smoking adenocarcinoma patients, 
pemetrexed–cisplatin was significantly superior 
to gemcitabine–cisplatin (Eli Lilly and Company. 
Data on file), with an identical adjusted h r of 0.82. 
Notably, in the uncommon large-cell subgroup, 
pemetrexed–cisplatin showed a h r of 0.67, and an 
important survival prolongation from 6.7 months to 
10.4 months.
Although it is true that no trial result is currently 
available comparing a pemetrexed–platinum doublet 
with a taxane–platinum doublet in non-squamous 
patients, such trials are underway. Nevertheless, it is 
highly unlikely that cisplatin–gemcitabine is inferior 
to a platinum–taxane combination in such patients: 
compare, for example, the control arms of a v a il (Avas-
tin in Lung Cancer) 46 and e c o g  4599 47 for o r r  and p f s, 
at 6.2 months and 20% versus 4.5 months and 15%. 
It is therefore reasonable to propose that cisplatin–
pemetrexed be considered a new standard of first-line 
care in patients with non-squamous disease.
A recent randomized phase ii study indicated that, 
in patients previously treated with cisplatin-based 
therapy, the addition of carboplatin to pemetrexed in 
the second line substantially improved p f s (h r : 0.67; 
p = 0.005) and o r r , but not survival. Patients with 
non-squamous disease did better, regardless of treat-
ment arm 48. This manoeuvre should be considered, 
because toxicity was very low.
I will shortly discuss another randomized trial 
(j m e n ) in the first line, in which pemetrexed main-
tenance resulted in a markedly differential effect by 
histology, consistent with j m d b  and j m e i . It is therefore 
now credible that pemetrexed–cisplatin is the current 
best chemotherapy for adenocarcinoma and large-cell 
disease in the first line, and that pemetrexed is the 
best available chemotherapy in the second-line in 
these histologies. Whether pemetrexed can be used 
in the first and the second line is uncertain, although VINCENT
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experience in other cancers suggests that patients that 
enjoy a good response in the first line, and a relatively 
long p f s, will often respond again to the same drug or 
drugs in the second line 49.
A small randomized trial has established that 
pemetrexed–carboplatin is even less toxic than 
gemcitabine–carboplatin, but in that trial (and unusu-
ally), no difference by histology was apparent, and 
women survived longer on pemetrexed–carboplatin 
(h r : 1.43; p = 0.022) 50.
3.2  Bevacizumab
Bevacizumab, an anti-v e g f  monoclonal antibody, has 
been added to first-line chemotherapy in two trials: 
e c o g  4599 47 and a v a il 46. In both trials, bevacizumab 
monotherapy was continued as maintenance. Eligibil-
ity was strictly limited to patients with non-squamous 
histology, no brain metastases, no significant he-
moptysis, and no current anticoagulant therapy. The 
e c o g  4599 trial, using carboplatin and paclitaxel, 
showed a 2-month survival benefit (10.3 months vs. 
12.3 months); but by subgroup, only men benefited. 
Women and men both enjoyed a substantial increase 
in o r r  and p f s. The adenocarcinoma patients ex-
perienced a large survival benefit [10.3 months vs. 
14.2 months: Sandler A, Yi J, Hambleton J, Kolb 
MM, Johnson DH. Treatment outcomes by tumor 
histology in Eastern Cooperative Group (e c o g ) 
study E4599 of bevacizumab (b v ) with paclitaxel/
carboplatin (p c) for advanced non-small cell lung 
cancer (n s c l c ). Presented at the 2008 Chicago Mul-
tidisciplinary Symposium in Thoracic Oncology; 
November 13–15, 2008; Chicago]. The a v a il trial, 
using cisplatin–gemcitabine, failed to show a sur-
vival benefit; however, o r r  and p f s again showed an 
important advantage. The m s t  for the a v a il control 
arm was unusually good, at 13.1 months—perhaps 
because a relatively high number of patients received 
post-discontinuation therapy.
A major and consistent advantage of bevacizumab 
is an increased response rate and p f s, thus potentially 
improving symptom control and time without symp-
tomatic deterioration 39 and also reducing the fraction 
of patients that progress during the first line, thus 
increasing by 5%–10% absolute the number suitable 
for maintenance. Bevacizumab is contraindicated in 
patients with squamous disease because of the risk 
of exsanguinating hemoptysis.
The conflicting survival data in the two major 
trials, e c o g  4599 and a v a il, have led to controversy re-
garding the ultimate value of bevacizumab; however, 
in respect of p f s and o r r , the benefits seem secure.
3.3  Cetuximab
Cetuximab is a monoclonal antibody directed against 
the extracellular domain of e g f r . In a large trial of 
first-line cisplatin–vinorelbine with or without 
cetuximab, survival was increased (h r: 0.803; 
p = 0.003), but only in Caucasian patients. Cetuximab 
may have a role in squamous carcinoma (h r: 0.794; 
m s t : 8.9 months vs. 10.2 months) and in patients in 
whom bevacizumab is contraindicated. Note that 
cetuximab was continued as maintenance after 
completion of the cisplatin–vinorelbine 51.
3.4	 Gefitinib
Gefitinib is widely used in East Asian patients because 
of a higher incidence of EGFR mutation, both in never-
smokers and in light ex-smokers (approximately 60% 
vs. 30% in Western countries) and even in heavier 
ex-smokers (approximately 30% vs. approximately 
10% in Western countries) 52. As mentioned, in EGFR-
mutated Asian never-smokers or light ex-smokers, 
gefitinib had statistically superior p f s and o r r  as 
compared with carboplatin–paclitaxel, but in the ap-
proximately 40% wild-type EGFR patients, gefitinib 
was markedly inferior to chemotherapy 45, with a 
1.1% o r r  and a very short p f s. This finding has led to 
the suggestion that in EGFR-unknown patients, che-
motherapy should be used in the first line, followed 
immediately by e g f r -t k i  maintenance.
In i n t e r e s t, in which gefitinib was non-inferior 
to docetaxel in the second line (and less toxic), 
biomarkers did not select for differential benefit. 
Notably, objective response in the KRAS-mutated 
patients on gefitinib was 0% (and only 3.5% in those 
on docetaxel) 44.
4.  MAINTENANCE THERAPY
Semantically, some practitioners prefer to restrict the 
term “maintenance” to trials in which the same first-line 
chemotherapy is continued beyond the 4–6 cycles of 
induction, in whole or in part, and to use “early second 
line” to describe the strategy of switching to another 
drug after induction, but before relapse. My preference 
is to use “maintenance” to describe either strategy.
Older trials showed no survival advantage for 
maintenance chemotherapy 53–56, but five recent trials 
indicate that such therapy should now be used. Bro-
dowicz et al. 57 randomized patients benefiting from 
4 cycles of induction cisplatin–gemcitabine to more 
gemcitabine or to observation. The p f s was better (h r : 0.7; 
p < 0.001) in the treated group; and in patients with 
a good performance status, o s  was markedly better 
(8.3 months vs. 22.9 months; h r : 0.48; p value signifi-
cant). Fidias et al. 58 tested, in patients benefiting from 
induction doublets (excluding docetaxel), whether 
maintenance docetaxel compared with delayed (that 
is, second-line) docetaxel (at relapse) would offer 
superior p f s. It did (h r : 0.71; p = 0.0001), and o s  
trended positively as well (9.7 months vs. 12.3 months; 
p = 0.0853). The large j m e n  59 study, similar in design, 
but comparing pemetrexed with placebo in mainte-
nance, showed a superior p f s, but only in patients with A-NSCLC: A PERSONAL VIEW
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non-squamous disease (1.84 months vs. 4.37 months; 
p < 0.00001). Note that the induction 4 cycles of 
platinum doublet chemotherapy did not include a 
pemetrexed option. Final survival data are markedly 
positive: 10.3 months versus 15.5 months measured 
from randomization (p = 0.002) and 11.5 months 
versus 16.8 months in the adenocarcinoma subgroup 
(p = 0.026). Note that the disease control rate contin-
ued to increase during maintenance pemetrexed, to 
49.1% from 28.9% (p < 0.09) in the entire intent-to-
treat population.
The j m e n  trial has been criticized because a 
relatively low proportion (19%) of the control arm 
received second-line pemetrexed. However, 29% 
received docetaxel, which although inferior to pem-
etrexed, is not so inferior as would account for much 
of the large o s  difference. Furthermore, approximately 
one third received an e g f r -t k i  (on both arms). This 
survival result, at the cost of minimal increases in 
grades 3 and 4 neutropenia (3% vs. 0%) and fatigue 
(5% vs. 1%) in a large (n = 663) well-conducted ran-
domized controlled trial, is very provocative. Note 
that the actual survival should be increased by the 
(at least) 3-month induction chemotherapy period; 
in the adenocarcinoma maintenance arm, the median 
survival should therefore be at least 19.8 months. 
However, this extension should be interpreted in the 
knowledge that some percentage (about 45% 58) of 
patients that start first-line therapy are not able to pro-
ceed to maintenance and probably experience a rather 
short survival. Thus, median o s  for adenocarcinoma 
patients as a whole, starting from day 1 of cycle 1, 
would not approach 19.8 months, but rather some-
what less. If the median survival of the immediately-
progressing patients was about 6 months, the median 
o s  for a postulated group of adenocarcinoma patients 
would decline to about 15 months. Note that the 
e c o g  4599 adenocarcinoma subgroup (more highly 
selected) on carboplatin–paclitaxel–bevacizumab 
achieved a median o s  of 14.2 months [Sandler A, Yi 
J, Hambleton J, Kolb MM, Johnson DH. Treatment 
outcomes by tumor histology in Eastern Coopera-
tive Group (e c o g ) study E4599 of bevacizumab (b v ) 
with paclitaxel/carboplatin (p c) for advanced non-
small cell lung cancer (n s c l c ). Presented at the 2008 
Chicago Multidisciplinary Symposium in Thoracic 
Oncology; November 13–15, 2008; Chicago].
The two trials s a t u r n  (Sequential Tarceva in 
Unresectable NSCLC) and at l a s (Adjuvant Ta-
moxifen—Longer Against Shorter) are looking at 
maintenance erlotinib, at l a s in the context of beva-
cizumab. Both have met their p f s endpoint. Of these 
two studies, s a t u r n  is of most immediate relevance 60. 
The h r  for p f s is 0.71, but the median p f s difference 
is negligible (12.3 weeks vs. 11.1 weeks). However, 
the mean p f s difference (22.4 weeks vs. 16 weeks) 
appears more worthwhile, and the o r r  (5.4% up to 
11.9%) and the disease control rate (50.8% up to 
60.6%) are increased. It does seem clear that certain 
subgroups benefited disproportionately 61, especially 
women (h r : 0.56), people of Asian ethnicity (h r : 
0.58), never-smokers (h r : 0.56), patients positive for 
EGFR mutation (h r : 0.10), those with EGFR positivity 
by fluorescence in situ hybridization [f i s h (h r :0.68)] 
or immunohistochemistry (h r : 0.69), and those with 
wild-type KRAS (h r : 0.70). Of course, many of those 
groups overlap; what is needed is a multivariate 
analysis to better define the beneficiaries. It will 
then be worth considering maintenance erlotinib in 
a selection of the foregoing subgroups, especially 
but perhaps not only EGFR-mutated cases. In the 
remaining subgroups, evidence that is more compel-
ling (that is, final o s  data, due in 2010) would be 
needed to consider maintenance erlotinib. The at l a s 
results were similar, except that biomarker data are 
still to be presented. Overall, mean p f s increased by 
1 month [3.75 months to 4.76 months (h r :0.722; 
p = 0.0012)], with people of Asian ethnicity, women, 
and never-smokers benefiting disproportionately. 
Data concerning o s  are due next year 62.
5.  ANCILLARY STRATEGIES
One meta-analysis supports the use of the anti-emetic 
NK1 antagonist aprepitant in cisplatin-based chemo-
therapy 63. Suggestive randomized data also support 
the use of zoledronic acid in patients with bone me-
tastases, even indicating a survival benefit (h r : 0.65; 
p < 0.001) 64. Prophylactic cranial irradiation could 
benefit patients with a high risk of brain metastases 65, 
as occurs with extensive small-cell lung cancer 66. 
Prophylactic anticoagulation should be explored in 
a-n s c l c , as in small-cell disease 67.
5.1  The Algorithm
In the absence of biomarkers, I would propose the 
general scheme shown in Figure 1 for fit patients 
needing systemic therapy.
Squamous carcinoma (Figure 2) should be 
managed using 4–6 cycles of a platinum doublet, 
particularly cisplatin–gemcitabine. Carboplatin is an 
alternative, and vinorelbine and paclitaxel are also 
f i g u r e  1   A suggested approach to the subgrouping of advanced 
non-small-cell lung cancer (a-n s C l C ) in the absence of biomarkers. 
Rx = prescription.VINCENT
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acceptable. Bevacizumab must be avoided, but cetux-
imab could be added in the first line. Maintenance 
could consist of cetuximab or docetaxel or erlotinib; 
observation alone is likely inferior. The second line 
should involve a crossover. Note that gefitinib use in 
the second line after docetaxel might be justified, but 
is not approved; the question of whether the higher-
dose philosophy of erlotinib confers an advantage 
with e g f r  overexpression is open.
Biomarkers are probably not mandated in 
squamous pathology, because mutated-type EGFR 
does not occur, mutated-type ras is rare, and e g f r  
overexpression by immunohistochemistry occurs in 
most patients. The role of e g f r  f i s h positivity needs 
better definition by histologic subtype.
Large-cell carcinoma patients (Figure 3) seem 
to benefit a great deal from pemetrexed-based che-
motherapy, as in the first-line j m d b  trial (h r:0.67; 
p = 0.03). In the j m e n  trial (pemetrexed mainte-
nance), the number of large-cell cases was small, 
but pemetrexed should be considered if the first-line 
experience was good. Use of bevacizumab did not 
yield a survival benefit in the subgroup analysis of 
E4599, and its use might be justified only to enhance 
response in the first line. In the second line, erlotinib 
might be justifiable (unless the tumour is mutated-
type KRAS or e g f r  f i s h-negative, or both), but data 
are scanty. Biomarker triage is not emphasized here, 
because information is scarce. The s a t u r n study has 
not yet separately reported maintenance data for 
erlotinib in large-cell disease.
Adenocarcinoma management (Figure 4) is now 
complex and challenging. The schema here shows 
what would be reasonable in the absence of bio-
markers. In this case, smoking status is the default 
triage. Cisplatin–pemetrexed is the established best 
first-line doublet, and use of pemetrexed in mainte-
nance very likely prolongs survival; maintenance 
with an e g f r -t k i  in never-smokers may be as good, 
especially in those of Asian ethnicity. Pemetrexed use 
in the first line and in maintenance, or alternatively 
in the first and second lines, is currently unsupported 
by data. If a choice has to be made, I would favour 
pemetrexed use for maintenance in ex- and current 
smokers (likely o s  benefit) and for the first line in 
never-smokers, followed by e g f r -t k i  maintenance. 
Because approximately 40% of adenocarcinomas in 
ex- and current smokers show mutated-type KRAS 
(especially if poorly differentiated), erlotinib use here 
should be a cautious last resort. The never-smokers 
do not harbour classical activating mutated-type 
KRAS. But a small fraction do seem to harbour non-
classical KRAS mutations of uncertain significance 68. 
The “right dose” of erlotinib in current smokers and 
recent ex-smokers may be 300 mg daily, because of 
enzyme induction 69, although this dose is not ap-
proved in Canada or anywhere else.
If biomarkers are available, then they should be 
the preferred triage over smoking status. Mutated-
type EGFR has now emerged as the biomarker of main 
interest, because it so clearly delineates a distinct 
entity eminently treatable with first-line e g f r -t k i  
(especially gefitinib, were it to be approved), which 
is less toxic than erlotinib.
In patients in Western countries with wild-type 
EGFR, the efficacy of e g f r -t k i s is uncertain; if these 
agents are effective, they are likely worthwhile mainly 
in patients with wild-type KRAS and f i s h-positive e g f r  
(Figure 5).
f i g u r e  2   Suggested management of squamous cell carcinoma of 
the lung. e g f r = epidermal growth factor receptor.
f i g u r e  3   Suggested management of large-cell carcinoma of the lung. 
e g f r = epidermal growth factor receptor.
f i g u r e  4   Suggested management of adenocarcinoma of the lung in 
the absence of biomarkers.A-NSCLC: A PERSONAL VIEW
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5.2  Adenocarcinomas and Molecular Testing
Table ii may be of assistance in respect of KRAS and 
EGFR mutational status in adenocarcinoma.
5.3	 A	Note	About	“Not	Otherwise	Specified”
Pathology reported as “NOS” (“not otherwise speci-
fied”) is not to be equated with large-cell disease. This 
result means either that the specimen was inadequate 
or that the cells are genuinely very undifferentiated, 
in which case mutated-type EGFR is very unlikely, 
and some additional guidance may be forthcoming 
from smoking status coupled with clinical features 
that commonly differentiate subtypes. For example, 
nonmetastatic hypercalcemia is probably exclusively 
found in squamous carcinomas. Table iii, which 
shows stereotypes, may assist.
6.  CONCLUSIONS
The algorithm provided here for a-n s c l c  patients with 
a good performance status may differ in some re-
spects from current practice in Canada. In particular, 
I believe that maintenance chemotherapy, or bio-
logic therapy, or both, should now be incorporated 
as a standard of care, although further optimization 
of drug and patient selection is a work in progress. 
For this reason, I do not believe that “all patients 
should get three lines of therapy.” Use of maintenance 
therapy may, in fact, remove a third-line option, but 
it guarantees that more people benefit. Furthermore, 
good evidence suggests that KRAS-mutant patients 
are generally not helped, and may be harmed, by 
e g f r-t k is. In patients with EGFR mutations, gefitinib 
is probably equivalent to erlotinib, but in patients 
with e g f r  overexpression, the erlotinib dosing phi-
losophy may hold an advantage over standard-dose 
gefitinib. I therefore believe that KRAS and EGFR 
testing should be available in adenocarcinoma pa-
tients, because “adenocarcinoma” is not a unitary 
entity. I suspect that the “right” dose of erlotinib in 
current and ex-smokers is 300 mg. I believe that the 
data with cisplatin–pemetrexed are good enough to 
justify first-line use both in adenocarcinoma and in 
large-cell disease. Bevacizumab should be consid-
ered to improve the depth of response, especially in 
patients with bulky or aggressive non-squamous 
disease. The role of bevacizumab in maintenance is 
debatable if chemotherapy or e g f r-t k i maintenance 
is to be used, but that agent should be considered. In 
patients with non-squamous disease, bevacizumab 
with carboplatin–paclitaxel may prolong survival, 
but cisplatin–pemetrexed may achieve the same 
survival even without bevacizumab. Cetuximab is a 
valid consideration in squamous carcinoma (and in 
other histologies if bevacizumab is contraindicated), 
but these two antibodies should not be used together. 
Never-smokers or light ex-smokers should receive 
cisplatin–pemetrexed followed immediately by 
maintenance with an e g f r-t k i; if they are known to 
have mutated-type EGFR, a first-line e g f r-t k i (either 
one) is acceptable, possibly with bevacizumab. Zole-
dronic acid use should be considered for patients at 
risk of a (or another) skeletal-related event, and pro-
phylactic cranial irradiation might be considered 
once the risk factors for brain metastases are better 
understood. Prophylactic anticoagulation should be 
considered in high-risk patients. Palliative radio-
therapy, and even surgery, should be considered for 
focal problems. Aprepitant improves the rate of con-
trol of cisplatin-induced nausea and vomiting.
If the foregoing measures are judiciously applied, 
the median survival for all types patients with a good 
performance status may exceed 1 year. Provincial 
provider agencies should carefully and responsibly 
consider the cost-effectiveness of these measures.
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